| Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia V Rocha, M Labopin, G Sanz, W Arcese, R Schwerdtfeger, A Bosi, ... New England Journal of Medicine 351 (22), 2276-2285, 2004 | 1069 | 2004 |
| Transplantation of ex vivo expanded cord blood EJ Shpall, R Quinones, R Giller, C Zeng, AE Baron, RB Jones, ... Biology of Blood and Marrow Transplantation 8 (7), 368-376, 2002 | 452 | 2002 |
| Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell … M de Lima, D Couriel, PF Thall, X Wang, T Madden, R Jones, EJ Shpall, ... Blood 104 (3), 857-864, 2004 | 404 | 2004 |
| Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term … M De Lima, A Anagnostopoulos, M Munsell, M Shahjahan, N Ueno, ... Blood 104 (3), 865-872, 2004 | 385 | 2004 |
| Cord-blood engraftment with ex vivo mesenchymal-cell coculture M De Lima, I McNiece, SN Robinson, M Munsell, M Eapen, M Horowitz, ... New England Journal of Medicine 367 (24), 2305-2315, 2012 | 366 | 2012 |
| Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a … M De Lima, S Giralt, PF Thall, L de Padua Silva, RB Jones, K Komanduri, ... Cancer 116 (23), 5420-5431, 2010 | 342 | 2010 |
| Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and … IF Khouri, P McLaughlin, RM Saliba, C Hosing, M Korbling, MS Lee, ... Blood 111 (12), 5530-5536, 2008 | 326 | 2008 |
| Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure M Duval, JP Klein, W He, JY Cahn, M Cairo, BM Camitta, R Kamble, ... Journal of clinical oncology 28 (23), 3730, 2010 | 311 | 2010 |
| Hematopoietic cell transplantation–specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC … ML Sorror, S Giralt, BM Sandmaier, M De Lima, M Shahjahan, ... Blood 110 (13), 4606-4613, 2007 | 280 | 2007 |
| Tumor necrosis factor-α blockade for the treatment of acute GVHD D Couriel, R Saliba, K Hicks, C Ippoliti, M De Lima, C Hosing, I Khouri, ... Blood 104 (3), 649-654, 2004 | 280 | 2004 |
| Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing KV Komanduri, LSS John, M De Lima, J McMannis, S Rosinski, I McNiece, ... Blood 110 (13), 4543-4551, 2007 | 277 | 2007 |
| Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial M De Lima, J McMannis, A Gee, K Komanduri, D Couriel, BS Andersson, ... Bone marrow transplantation 41 (9), 771-778, 2008 | 260 | 2008 |
| Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect KW Van Besien, M De Lima, SA Giralt, DF Moore Jr, IF Khouri, G Rondon, ... Bone marrow transplantation 19 (10), 977-982, 1997 | 255 | 1997 |
| Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD DR Couriel, C Hosing, R Saliba, EJ Shpall, P Anderlini, B Rhodes, ... Blood 107 (8), 3074-3080, 2006 | 250 | 2006 |
| Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid … E Estey, M De Lima, R Tibes, S Pierce, H Kantarjian, R Champlin, S Giralt Blood 109 (4), 1395-1400, 2006 | 237 | 2006 |
| Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells SN Robinson, J Ng, T Niu, H Yang, JD McMannis, S Karandish, I Kaur, ... Bone marrow transplantation 37 (4), 359, 2006 | 226 | 2006 |
| Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation DR Couriel, RM Saliba, S Giralt, I Khouri, B Andersson, M de Lima, ... Biology of blood and marrow transplantation 10 (3), 178-185, 2004 | 216 | 2004 |
| Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia HM Kantarjian, S O'Brien, JE Cortes, SA Giralt, MB Rios, J Shan, FJ Giles, ... Blood 100 (5), 1590-1595, 2002 | 211 | 2002 |
| Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working … CA Rodrigues, G Sanz, CG Brunstein, J Sanz, JE Wagner, M Renaud, ... Hematology, 2007 | 206 | 2007 |
| Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for iv BuCy2 in chronic myelogenous leukemia BS Andersson, PF Thall, T Madden, D Couriel, X Wang, HT Tran, ... Biology of Blood and Marrow Transplantation 8 (9), 477-485, 2002 | 201 | 2002 |
